
ProKidney Corp. (NASDAQ:PROK – Free Report) – Analysts at HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for shares of ProKidney in a research report issued to clients and investors on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.05 for the year, down from their previous forecast of $0.08. The consensus estimate for ProKidney’s current full-year earnings is ($0.57) per share.
ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.12 million.
PROK has been the topic of several other reports. Citigroup reduced their price target on ProKidney to $8.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ProKidney has an average rating of “Moderate Buy” and a consensus target price of $10.00.
Check Out Our Latest Analysis on PROK
ProKidney Trading Up 5.8%
ProKidney stock opened at $1.10 on Monday. The stock has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $1.76. ProKidney has a 12 month low of $0.87 and a 12 month high of $2.65.
Insider Activity at ProKidney
In other news, Director Brian Pereira sold 222,948 shares of ProKidney stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.42, for a total transaction of $316,586.16. Following the transaction, the director owned 54,103 shares in the company, valued at approximately $76,826.26. The trade was a 80.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 39.83% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of PROK. Russell Investments Group Ltd. grew its position in shares of ProKidney by 163.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 15,958 shares of the company’s stock valued at $26,000 after buying an additional 9,908 shares during the last quarter. SummitTX Capital L.P. acquired a new stake in shares of ProKidney in the first quarter valued at about $26,000. Cetera Investment Advisers acquired a new stake in shares of ProKidney in the third quarter valued at about $27,000. StoneX Group Inc. bought a new position in shares of ProKidney during the third quarter worth about $30,000. Finally, Voya Investment Management LLC bought a new position in shares of ProKidney during the third quarter worth about $37,000. 51.59% of the stock is owned by institutional investors.
ProKidney Company Profile
ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.
Read More
- Five stocks we like better than ProKidney
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
